Though GSK has put considerable effort into developing pharmacological treatments for gynecological cancers—including Zejula, ...

A curated review of what has happened in endometrial cancer research in 2024, including expert commentary, FDA approvals, healthcare disparities, AI, immunotherapies, and more.

MI Cancer Seek has received approval from the FDA as a companion diagnostic test to identify those who may benefit from ...

Top-line Phase 2b data anticipated for ANB032, our BTLA agonist, in atopic dermatitis (AD) in December 2024 Top-line Phase 2b data anticipated for rosnilimab, our PD-1 agonist, in rheumatoid arthritis ...

For the most current information about the device indications for the therapeutic products in this group, go to: ...

Mark A. Lewis, MD, discusses dostarlimab-gxly and how experts can best counsel patients with locally advanced mismatch repair ...

GSK's Q3 earnings beat estimates but sales miss the same. The company also lowers its outlook for vaccine sales for the rest of the year due to weak U.S. demand.

A screenshot of the ABC News-hosted presidential debate between Kamala Harris and Donald Trump in September 2024. Picture: Youtube screenshot of Wall Street Journal debate stream Half of the world ...

GSK has moved a step closer to approval of its cancer immunotherapy Jemperli as a first-line treatment for endometrial cancer in the EU. The EMA has started its review of the PD-1 inhibitor in ...

NEWS ANALYSIS: Norwegian Prime Minister Jonas Gahr Støre was quick to congratulate Donald Trump on Wednesday, even before the final vote in the US presidential election was tallied. Støre stressed ...

The UK-headquartered drugmaker has also struggled to make headway with PARP inhibitor Zejula (niraparib), like Jemperli a drug that it acquired as part of its $5.1 billion takeover of Tesaro in 2019.